Company news
Alk-abello A/s Class B (OMXCOP:ALK_B) news
Every Alk-abello A/s Class B press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
ALK upgrades its full-year outlook
May 4, 2026
Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026
April 28, 2026
Annual General Meeting in ALK-Abelló A/S held on 16 March 2026
March 16, 2026
New data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors
March 4, 2026
Annual General Meeting in ALK-Abelló A/S on 16 March 2026
February 20, 2026
Henriette Mersebach to step down as ALK’s head of R&D
February 20, 2026
Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026
February 13, 2026
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, includin...
February 2, 2026
ALK receives positive recommendation for EURneffy® 1 mg: A needle-free anaphylaxis treatment for children
January 29, 2026
ALK to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco
January 8, 2026
ALK – Financial calendar for the 2026 financial year
December 22, 2025
Major shareholder announcement
December 19, 2025
ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America
December 1, 2025
Nine-month interim report (Q3) 2025 (unaudited)
November 12, 2025
Invitation to the presentation of ALK’s first nine months (Q3) 2025 results on Thursday, 13 November 2025
November 6, 2025
ALK and GenSci partner to expand the AIT market in China
September 17, 2025
Real-world evidence supports clinical effectiveness of the neffy® nasal adrenaline spray
September 8, 2025
ALK expands the Executive Leadership Team to include key commercial regions
September 4, 2025
Six-month interim report (Q2) 2025 (unaudited)
August 21, 2025
Invitation to the presentation of ALK’s first six months (Q2) 2025 results on Thursday, 21 August 2025
August 14, 2025
ALK upgrades its full-year revenue outlook
August 12, 2025
ALK’s tree pollen tablet (ITULAZAX®) now recommended by NICE for use in the UK health system
July 21, 2025
EURneffy® approved as the first needle-free anaphylaxis treatment of adults and children in the UK
July 18, 2025
First market launch of the adrenaline nasal spray, EURneffy®, for treatment of adults and children in Germany
June 26, 2025
ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025
June 16, 2025
ALK participates at Jefferies Global Healthcare Conference 2025 in New York
June 4, 2025
ITULATEK® approved for treatment of children and adolescents in Canada
May 8, 2025